跳转至内容
Merck
CN

SML3653

Triptorelin pamoate

≥95% (HPLC)

别名:

Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 pamoate salt, Triptorelin ebonate, [D-Trp6]-LH-RH pamoate

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
C64H82N18O13·xC23H16O6
化学文摘社编号:
UNSPSC Code:
51111800
NACRES:
NA.25
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

OC1=C(CC2=C(O)C(C(O)=O)=CC3=C2C=CC=C3)C4=C(C=CC=C4)C=C1C(O)=O.O=C([C@H](CC5)NC5=O)N[C@@H](CC6=CN=CN6)C(N[C@@H](CC7=CNC8=C7C=CC=C8)C(N[C@@H](CO)C(N[C@@H](CC9=CC=C(O)C=C9)C(N[C@H](CC%10=CNC%11=C%10C=CC=C%11)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N%12[C@H](

assay

≥95% (HPLC)

form

(Powder or lyophilized powder or film)

mol wt

1311.45 g/mol

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

Quality Level

Biochem/physiol Actions

Synthetic LHRH agonist analog
Triptorelin pamoate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.

Disclaimer

Hygroscopic

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Giulia Marvaso et al.
Anticancer research, 38(5), 3139-3143 (2018-05-02)
Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB). A retrospective
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study
BMC Urology, 18(1), 23-23 (2018)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持